As AstraZeneca’s share price dips 4%, is it time for me to buy more?

Despite its 12-month increase, AstraZeneca’s share price appears very undervalued to me, and looks set to rise on strong growth to 2030.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Hand of person putting wood cube block with word VALUE on wooden table

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca’s (LSE: AZN) share price has dropped around 4% from its 26 June 12-month traded high of £127.04.

However, this still leaves it about 28% up from its 12-month low of 12 February.

As a shareholder who bought at much lower prices, is now a good time for me to buy more?

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

How does it look technically?

AstraZeneca trades on the key price-to-earnings ratio (P/E) of stock valuation measurement at 38.8. This is still bottom of the list of its key international peers, which have an average P/E of 90.4.

This comprises Novo Nordisk at 45.2, AbbVie at 51.5, Eli Lilly at 127, and Merck at 138.1.

That said, its closest UK peer – GSK – has a P/E of 13.8, which according to my analysis is around 67% undervalued against its own peer group.

However, AstraZeneca is much bigger than GSK – ranked globally by market capitalisation respectively at number seven and number 18. 

Using the same discounted cash flow methodology as I did for GSK, AstraZeneca is 42% undervalued at its current £122.55.

Therefore, a fair value for the shares would be £211.29, although they may go lower or higher than that.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL23 Jul 201923 Jul 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Growth projections

Back in 2014, AstraZeneca announced its target of increasing revenues to more $45bn+ by 2023 (from the then-$26.5bn). Didid it make it? Yes, revenues came in at $45.8bn.

In its recent 21 May ‘Ambition 2030 and Beyond’ presentation, it said it will deliver $80bn in revenues by 2030.  

It added that it is on track to deliver mid-30% core operating margin by 2026. After that, it will still target at least mid-30%, although it said this will be influenced by portfolio evolution.

Its Q1 2024 results released on 25 April showed revenue up 19% year on year to $12.679bn. That was driven by an 18% increase in product sales.

One risk to the firm’s projections is that a failure in any of its key drugs could be very costly. Also potentially very expensive would be any legal action arising from the ill effects of any of its medicines.

That said, consensus analysts’ expectations are that AstraZeneca’s earnings will grow 15.7% a year to end-2026. Earnings per share are anticipated to increase 16.5% a year to that point.

So will I buy?

As a long-term investor now rather than the trader I was when younger, I am in an investment for the duration, at least until I sell my remaining growth stocks and focus solely on high-dividend-paying ones.

That said, my average entry price for my AstraZeneca holding is a lot lower than the current price. To buy more at this level would dramatically increase the risk of any major adverse price moves on my profit.

Consequently, I am happy with my current position and will not buy more.

However, if I did not have this I would have no hesitation in starting a position at the current price. I think there is every chance that AstraZeneca will achieve its new growth targets, just as it did before.

And at roughly double the current revenues, these should drive the share price higher over time, in my view.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »